Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday

Key Points

• Amylyx Pharmaceuticals is set to release its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.43) per share.
• The company's stock has shown variable performance, with a 12-month high of $8.72 and a low of $1.76, currently trading at around $8.03.
• Recent research ratings for Amylyx Pharmaceuticals show an average rating of "Moderate Buy" and an average target price of $11.75.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.43) per share for the quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.03. On average, analysts expect Amylyx Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Trading Up 0.8%

Shares of AMLX opened at $8.03 on Friday. The company has a market capitalization of $715.79 million, a PE ratio of -2.58 and a beta of -0.49. Amylyx Pharmaceuticals has a 12 month low of $1.76 and a 12 month high of $8.72. The stock's 50-day moving average price is $6.45 and its two-hundred day moving average price is $4.78.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A hedge fund recently raised its stake in Amylyx Pharmaceuticals stock. Goldman Sachs Group Inc. lifted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 7.7% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,002,961 shares of the company's stock after buying an additional 143,065 shares during the period. Goldman Sachs Group Inc. owned approximately 2.25% of Amylyx Pharmaceuticals worth $7,090,000 at the end of the most recent reporting period. 95.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. UBS Group raised Amylyx Pharmaceuticals to a "hold" rating in a research report on Tuesday, June 24th. TD Cowen assumed coverage on Amylyx Pharmaceuticals in a research report on Friday, May 30th. They issued a "buy" rating for the company. Guggenheim assumed coverage on Amylyx Pharmaceuticals in a research report on Tuesday, June 24th. They issued a "buy" rating and a $17.00 price objective for the company. Mizuho lifted their price objective on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. Finally, Jefferies Financial Group started coverage on Amylyx Pharmaceuticals in a research report on Tuesday, June 24th. They issued a "hold" rating for the company. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $11.75.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.